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ABSTRACT:
The quantitative impact of excretory transport modulation on the
systemic exposure to xenobiotics and derived metabolites is
poorly understood. This article presents fundamental relationships
between exposure and loss of a specific excretory process that
contributes to overall clearance. The mathematical relationships
presented herein were explored on the basis of hepatic excretory
data for polar metabolites formed in the livers of various transport-
er-deficient rodents. Experimental data and theoretical relation-
ships indicated that the fold change in exposure is governed by the
relationship, 1/(1  fe), where fe is the fraction excreted by a particular
transport protein. Loss of function of a transport pathway associated
with fe < 0.5 will have minor consequences (<2-fold) on exposure, but
exposure will increase exponentially in response to loss of function of
transport pathways with fe > 0.5. These mathematical relationships
may be extended to other organs, such as the intestine and kidney, as
well as to systemic drug exposure. Finally, the relationship between
exposure and fe is not only applicable to complete loss of function of
a transport pathway but also can be extended to partial inhibition
scenarios by modifying the equation with the ratio of the inhibitor
concentration and inhibition constant.
Quantitative methods to predict the change in drug exposure result-
ing from drug-drug interactions occurring at the level of excretory
transport have not been fully developed. A fundamental understanding
of the effect of excretory transport modulation on drug/metabolite
exposure is presently lacking. Kinetic approaches originally used to
examine issues related to drug metabolism, such as the relative activ-
ity factor method, are now being applied to transport processes
(Hirano et al., 2004). In this article, the equation describing the effect
of inhibition of drug metabolism on systemic concentrations (Row-
land and Matin, 1973) is adapted to explore the effect of transport
modulation on exposure.
Hepatobiliary excretion data for polar metabolites generated in
perfused livers of various transporter-deficient animals are used pri-
marily in this article as supporting evidence for the theoretical equa-
tions. However, the relationships presented are applicable to any
organ such as the intestine and kidney in which the formed metabo-
lites can be excreted into two distinct compartments. Most impor-
tantly, the relationship describing the fold change in exposure is
applicable not only to an isolated organ but also to the systemic
exposure of drugs and metabolites when systemic clearance is medi-
ated by excretory transport. This article provides proof that the max-
imum fold change in exposure to a drug or metabolite cleared by
active excretion is dictated by the relationship 1/(1  fe), where fe is
the fraction of total clearance mediated by the ablated transport
protein. Although the equations presented may seem to be theoreti-
cally obvious, extensive experimental proof of these relationships
currently does not exist in the literature. The relationship, 1/(1  fe),
forms the basis for predicting the importance of a given excretory
transport pathway as a potential site for drug-drug interactions.
Results
Clearance-Exposure Relationship. The fold increase (fold ) in
systemic drug exposure caused by inhibition of metabolism has been







where fm is the fraction of total clearance mediated by the relevant
enzyme, [I] is the inhibitor concentration, and KI is the inhibitor
concentration at which enzyme activity is impaired 50% when sub-
strate concentrations are below the Michaelis-Menten constant (KM).
When [I]  KI, the increase in systemic drug exposure is only a





This relationship is equally valid for complete genetic deficiency of an
enzymatic pathway, where fm is determined at “normal” expression of
the enzyme. Equation 2 indicates that at most, a 2-fold increase in
systemic exposure will be observed when fm is 0.5, even when
inhibition of the relevant enzyme is complete. In contrast, systemic
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exposure will increase exponentially in response to complete inhibi-
tion or knockout of the enzyme as fm increases from 0.5 to 1.
In the case of drug transport, the relevant parameter is fe, the
fraction of total clearance mediated by a particular excretory transport
protein, as opposed to fm. However, the mathematical relationships are
analogous. When a particular route of transport is inhibited com-





Metabolism and excretory transport function in concert to clear drugs
from the body. In cases in which both metabolic and transport pro-
cesses contribute to the overall clearance, the sum of fm and fe must
equal 1, such that these fractions are calculated relative to total
clearance and not metabolic or excretory clearance in isolation.
Note that all equations presented assume first-order kinetics. Trans-
port proteins and drug-metabolizing enzymes are inherently capacity-
limited and therefore nonlinear. All of the relationships presented
herein assume approximate linear kinetic behavior, and thus all sub-
strate concentrations are assumed to be below the KM of the relevant
transport protein.
In the case of hepatic transport (i.e., excretion from the hepatocyte
across the basolateral membrane into blood or across the canalicular
membrane into bile) (Fig. 1), this fundamental relationship can be
illustrated most clearly by considering the excretion of polar metab-
olites formed in the liver. In this case, the resultant influence of
changes in excretory transport on systemic exposure is not con-
founded by the kinetics of drug uptake into the liver or passive
membrane permeability. Furthermore, it is assumed that all probe
substrates are not further metabolized, such that excretion is the only
mechanism of clearance from the liver.
Unlike fm, the impact of fe on changes in exposure differs when the
knocked-out or inhibited transport protein mediates or opposes the
excretory route (apical or basolateral) of interest. For example, knock-
out or inhibition of a canalicular transport protein will result in
decreased biliary metabolite recovery, whereas knockout or inhibition
of a basolateral excretory transport protein will result in a higher
driving force for biliary excretion (i.e., increased hepatic metabolite
concentration) and therefore increased biliary metabolite recovery,
assuming that a compensatory protein exists on the canalicular mem-
brane with adequate affinity and capacity to transport the metabolite
into bile.
Decrease in Excretion via Inhibition/Knockout of Direct Trans-
port. When knockout or inhibition of a transport protein mediating
metabolite excretory clearance in the direction of interest is consid-
ered, fe is calculated on the basis of the decrease in the excretory













where fe, Bile and fe, B/L refer to the fraction excreted by a canalicular
or basolateral transport protein of interest, ClBile and ClB/L are the
biliary and basolateral intrinsic excretory clearances, and WT and KO
refer to the wild-type and transporter knockout/deficient animals,
respectively. In other words, fe is a function of the fraction of vectorial
flux mediated by the transport protein of interest.
Compensatory Increase in Excretion via Inhibition/Knockout
of Opposing Transport. When a competing transport mechanism on
the opposite plasma membrane domain is knocked out or inhibited,
the increase in excretion in the opposite direction is a function of the
fraction of total hepatic excretory clearance (i.e., the sum of ClBile and















In this case, the change in fe is not caused directly by the impaired
transport in the opposing direction but rather by the decrease in total
excretory clearance, which elicits an increase in hepatic concentra-
tions of the metabolite that serve as the driving force for increased
excretion in the direction of interest.
Effect of Excretory Transport Inhibition/Knockout on Organ
Exposure. The increase in hepatic metabolite concentrations in re-
sponse to transport inhibition is governed not by the fe of a particular
transport pathway, but by the change in total hepatic excretory clear-
ance. The relationship also would be governed by the fe (eq. 5) if other
transport processes were not altered in the knockout animal or if
inhibitors were specific enough not to affect other transporters. How-
ever, rodents genetically deficient in transporters may exhibit alter-
ations in other pathways, and inhibitors often affect multiple processes
(for review, see Zamek-Gliszczynski et al., 2006a). Thus, the change
in hepatic exposure to a derived metabolite is governed by the total












where ClTotal is the sum of the biliary and basolateral excretory
clearances. Total excretory clearance in an animal genetically defi-
cient in a transport protein may actually be higher than that in the
corresponding wild type, and in this case the relationship on the right
should be used to maintain the fe, Total between zero and unity.
Figure 2 demonstrates the applicability of eq. 3 in predicting the
fold change in biliary, systemic, or hepatic exposure to polar metab-
olites formed in the liver. These data were generated in single-pass
liver perfusion experiments in which the biliary and perfusate (sys-
temic) recovery of substrates could be quantified directly (Takenaka
et al., 1995; Xiong et al., 2002; Nezasa et al., 2006; Zamek-Gliszc-
zynski et al., 2006b,c). Rodents genetically deficient in a specific










FIG. 1. Scheme depicting the bidirectional hepatic excretion of
metabolites. All supporting data were generated in single-pass
liver perfusion experiments in which the livers were perfused
with parent compounds, and the recovery of relevant metabo-
lites in bile and perfusate, as well as steady-state hepatic me-
tabolite concentrations, were quantified directly.
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gation of the transporter on exposure/cumulative recovery. In this
experimental paradigm, biliary and perfusate recoveries serve as sur-
rogates for intestinal and systemic metabolite exposure, respectively.
Altered exposure/recovery of 4-methylumbelliferyl glucuronide
(4MUG) in Mrp3 and Bcrp knockout mice (Tables 1–3) will be used
to illustrate the application of the theoretical relationships. In mice,
4MUG is excreted into bile by Bcrp and across the hepatic basolateral
membrane into blood by Mrp3 (Zamek-Gliszczynski et al., 2006a);
therefore, biliary excretion of 4MUG would be expected to be im-
paired in Bcrp-knockout mice but would be elevated in mice lacking
Mrp3, a transport pathway that opposes the excretory route of interest.
Because Bcrp is directly involved in transporting 4MUG into bile,
using eq. 4.1 and the excretory clearance values (ClBileWT  88 l/min/g
liver and ClBile
KO  24 l/min/g liver) reported by Zamek-Gliszczynski
et al. (2006c), fe, Bile of Bcrp is calculated to be 0.73. Equation 3
predicts the decrease in biliary recovery of 4MUG to be 3.7-fold;
experimentally a 2.1-fold decrease was observed. In contrast, Mrp3
functions in the opposite direction from biliary excretion, so using eq.
5.1 and excretory clearance values (ClB/L
WT  259 l/min/g liver,
ClBile
WT  30 l/min/g liver, and ClB/L
KO  36 l/min/g liver) reported by
Zamek-Gliszczynski et al. (2006b), fe, Bile of Mrp3 is calculated to be
0.77. Equation 3 predicts the increase in biliary recovery of 4MUG to
be 4.4-fold; experimentally a 5.4-fold increase was observed. By
using eq. 6 and the same data set (ClTotal
WT  259  30 l/min/g liver
and ClTotal
KO  36  59 l/min/g liver), fe, Total of Mrp3 is calculated
to be 0.67. Equation 3 predicts that hepatic 4MUG exposure in
Mrp3-knockout mice will be 3.0-fold higher relative to that of wild-
type mice; experimentally an increase of 2.4-fold was observed.
Discussion
The fold change in exposure to polar metabolites in response to
modulation of hepatic excretory transport is described by eq. 3, 1/(1 
fe). Although the change in metabolite exposure resulting from mod-
ulation of hepatic excretory transport can be predicted by complex
physiologically based models of hepatobiliary pharmacokinetics
(Chiba and Pang, 1993; Liu and Pang, 2006), the theoretical relation-
ships presented in this article provide a simple and reliable prediction
of the impact of excretory transport modulation on exposure. Hepa-
tobiliary disposition data were used to support the relationship be-
tween exposure and fe, because of the existing wealth of data in the
liver. However, as demonstrated below, the relationships presented
herein are applicable to overall systemic drug/metabolite exposure as
well as to any organ.
The relationship, 1/(1  fe), is applicable to systemic exposure of
parent drug. This point is exemplified by elevated pravastatin expo-
sure in Mrp2-deficient rats. In normal bile duct-cannulated rats, 81%
of the intravenous pravastatin dose was excreted in bile (Adachi et al.,
1996). Mrp2 was shown to transport pravastatin in vitro (Sasaki et al.,
2002). If it is assumed that Mrp2 entirely mediated the biliary excre-
tion of pravastatin and assigned it an fe value of 0.81, then the
expected increase in drug exposure in rats lacking this transporter
would be approximately 5.3-fold (eq. 3). Relative to wild-type rats,
Mrp2-deficient rats exhibited 4.7- and 6.1-fold higher drug exposure
after intravenous and oral administration of pravastatin, respectively
(Kivisto et al., 2005).
The role of Bcrp in renal excretion of the sulfate metabolite of
E3040 was studied in mice (Mizuno et al., 2004). Renal excretory
clearance of E3040 sulfate was decreased from 2.35 to 0.59 ml/min/kg
in Bcrp-knockout mice. Thus, the fe of Bcrp in urinary excretion of
E3040 sulfate is 0.75 (eq. 4), and so the maximal expected decrease
in urinary recovery of this metabolite in knockout mice is 4-fold (eq.
3). Experimentally, urinary recovery of E3040 sulfate was decreased
approximately 3-fold.
The relationships presented in this article are based on data gener-
ated in rodents genetically deficient in specific transport proteins, but
eq. 3 could be modified as follows to describe transport inhibition:
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FIG. 2. A, fold change in biliary recovery as a function of the fraction excreted
(fe, Bile). B, fold change in perfusate recovery (a surrogate of systemic exposure) as
a function of the fraction excreted (fe, B/L). C, fold change in hepatic metabolite
concentration as a function of total fraction excreted (fe, Total). Solid line represents
the theoretical relationship (eq. 3) 50% represented by dashed lines. Data pre-
sented are summarized in Tables 1, 2, and 3.







The change in exposure as a function of fe at various I]/KI ratios is
presented in Fig. 3. In the case of inhibition, the inhibitor concentra-
tion must exceed KI for a transport pathway representing fe  0.5 to
observe appreciable (2-fold) changes in drug/metabolite exposure.
Note that the fold change in systemic and biliary exposure in the
presence of an inhibitor may be oversimplified by eq. 7, because many
inhibitors impair multiple transport mechanisms on both plasma
membrane domains (Zamek-Gliszczynski et al., 2006a). In contrast,
fe, Total, which determines the fold change in hepatic exposure, ac-
counts for the nonspecific effects of inhibitors.
TABLE 1
Fraction excreted (fe, Bile) by the ablated transport pathway in each animal model and the corresponding experimentally observed fold change in biliary recovery
Please note that fe, Bile values for canalicular transporters pumping directly into the bile were calculated using eq. 4.1, whereas fe, Bile for basolateral transporters pumping in the opposite
direction (into perfusate) were calculated using eq. 5.1. Positive fold  values indicate an increase in exposure, whereas decreased exposure is denoted by a negative fold  value. All data
points were calculated using mean values reported in the literature (Takenaka et al., 1995; Xiong et al., 2002; Nezasa et al., 2006; Zamek-Gliszczynski et al., 2006b,c).
Metabolite







fe, Bile Fold  fe, Bile Fold  fe, Bile Fold  fe, Bile Fold  fe, Bile Fold  fe, Bile Fold 
AS 0.85 3.4 0.00 1.2 0.87 5.8 0.00 1.6 0.17 1.8 0.21 1.0
AG 0.99 511.8 0.10 2.5 0.86 4.5 0.29 1.5 0.96 7.3 0.00 1.4
4MUS ND ND 0.00 1.0 1.00 631.3 0.00 1.1 0.35 1.4 0.44 1.0
4MUG ND ND 0.33 2.0 0.73 2.1 0.00 1.3 0.77 5.4 0.00 1.2
HS ND ND 0.00 1.1 0.99 66.4 0.00 1.1 0.13 1.2 0.21 1.2
HG ND ND 0.21 1.0 0.96 15.0 0.09 1.2 0.26 1.6 0.09 1.3
CDF ND ND 1.00 1740.7 0.00 1.4 ND ND ND ND ND ND
E3040S 0.00 1.2 ND ND ND ND ND ND ND ND ND ND
E3040G 0.97 36.5 ND ND ND ND ND ND ND ND ND ND
P-gp, P-glycoprotein; AS, acetaminophen sulfate; AG, acetaminophen glucuronide; 4MUS, 4-methylumbelliferyl sulfate; HS, harmol sulfate; HG, harmol glucuronide; CDF, carboxydichlo-
rofluorescein; E3040S, E3040 sulfate; E3040G, E3040 glucuronide; ND, not determined.
TABLE 2
Fraction excreted (fe, B/L) by the ablated transport pathway in each animal model and the corresponding experimentally observed fold change in perfusate recovery, a surrogate of systemic
exposure
Please note that fe, B/L values for basolateral transporters pumping directly into perfusate were calculated using eq. 4.2, whereas fe, B/L for canalicular transporters pumping in the opposite
direction (into the bile) were calculated using eq. 5.2. Positive fold  values indicate an increase in exposure, whereas decreased exposure is denoted by a negative fold  value. All data points











fe, B/L Fold  fe, B/L Fold  fe, B/L Fold  fe, B/L Fold  fe, B/L Fold  fe, B/L Fold 
AS 0.03 1.1 0.00 1.0 0.05 1.1 0.00 1.1 0.18 1.6 0.22 1.5
AG 0.49 2.4 0.00 1.4 0.01 1.2 0.00 1.1 0.96 5.9 0.00 1.1
4MUS ND ND 0.00 1.0 0.37 1.5 0.00 1.1 0.50 1.6 0.64 1.6
4MUG ND ND 0.04 1.2 0.08 1.0 0.00 1.1 0.86 3.3 0.00 1.2
HS ND ND 0.00 1.1 0.65 3.1 0.00 1.2 0.28 2.0 0.44 2.2
HG ND ND 0.13 1.1 0.56 2.7 0.05 1.2 0.62 3.0 0.21 1.3
CDF ND ND 0.57 2.6 0.00 1.1 ND ND ND ND ND ND
E3040S 0.00 1.1 ND ND ND ND ND ND ND ND ND ND
E3040G 0.62 2.9 ND ND ND ND ND ND ND ND ND ND
P-gp, P-glycoprotein; AS, acetaminophen sulfate; AG, acetaminophen glucuronide; 4MUS, 4-methylumbelliferyl sulfate; HS, harmol sulfate; HG, harmol glucuronide; CDF, carboxydichlo-
rofluorescein; E3040S, E3040 sulfate; E3040G, E3040 glucuronide; ND, not determined.
TABLE 3
Total fraction excreted (fe, Total; eq. 6) by the ablated transport pathway in each animal model and the corresponding experimentally observed fold change in hepatic
metabolite concentration in animal models lacking various transporter proteins
Positive fold  values indicate an increase in exposure, whereas decreased exposure is denoted by a negative fold  value. All data points were calculated using mean values reported in the
literature (Takenaka et al., 1995; Xiong et al., 2002; Nezasa et al., 2006; Zamek-Gliszczynski et al., 2006b,c). Hepatic concentrations were not quantified for carboxydichlorofluorescein











fe, Total Fold  fe, Tota Fold  fe, Tota Fold  fe, Tota Fold  fe, Tota Fold  fe, Tota Fold 
AS 0.43 1.1 0.03 1.2 0.38 1.3 0.02 1.3 0.14 1.2 0.21 1.1
AG 0.73 2.4 0.70 3.0 0.44 1.2 0.14 1.1 0.95 6.1 0.31 1.1
4MUS ND ND 0.43 1.9 0.44 1.6 0.17 1.4 0.40 1.5 0.60 1.8
4MUG ND ND 0.35 1.4 0.43 1.2 0.42 1.6 0.67 2.4 0.32 1.3
HS ND ND 0.04 1.2 0.23 1.3 0.22 1.4 0.10 1.4 0.28 1.2
HG ND ND 0.15 1.1 0.23 1.2 0.22 1.0 0.10 1.0 0.06 1.1
P-gp, P-glycoprotein; AS, acetaminophen sulfate; AG, acetaminophen glucuronide; 4MUS, 4-methylumbelliferyl sulfate; HS, harmol sulfate; HG, harmol glucuronide; ND, not determined.
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Systemic clearance of methotrexate in rats is partially mediated by
biliary excretion via Mrp2; the fe of this transport protein in systemic
elimination of methotrexate is approximately 0.5 (Chen et al., 2003).
In Mrp2-deficient rats, eq. 3 predicts a 2-fold increase in systemic
exposure to methotrexate, which is in good agreement with the 1.9-
fold increase observed by Chen et al. (2003). However, if Mrp2
function is not lost altogether, but instead inhibited to a limited extent,
a less pronounced increase in exposure would be expected. The KI of
probenecid for Mrp2 was determined to be 180 M in vitro, and this
inhibitor was intravenously infused to four different steady-state con-
centrations in wild-type rats to study its effect on methotrexate sys-
temic exposure (Ueda et al., 2001). Equation 7 predicts 1.1-, 1.4-, 1.4-,
and 1.5-fold increases in exposure at circulating probenecid concen-
trations of 243, 633, 704, and 905 M, respectively. This prediction
is in good agreement with the observed 1.2- and 1.3-fold increases in
methotrexate exposure at 243 and 633 M probenecid concentrations.
However, 1.9- and 2.1-fold observed increases in drug exposure at
704 and 905 M inhibitor concentrations exceeded the prediction,
because at these higher concentrations, probenecid also was apprecia-
bly inhibiting hepatic uptake of methotrexate in addition to its biliary
excretion (Ueda et al., 2001).
Theoretical relationships supported by experimental data indicate
that a considerable change in drug or metabolite exposure will occur
only when an appreciable excretory transport pathway (fe  0.5) is
inhibited substantially or knocked out. To elicit a considerable change
in exposure with an inhibitor, the fe of the impaired pathway must
exceed 0.5 and the [I]/KI ratio must exceed 1. As the fe of the
extensively inhibited or knocked-out transport pathway increases
above 0.5 and approaches unity, exposure will increase in an expo-
nential manner.
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FIG. 3. Fold change in exposure as a function of fe at various [I]/KI ratios as
described by eq. 7.
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